Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Prediction of cross-recognition of peptide-HLA A2 by Melan-A-specific cytotoxic T lymphocytes using three-dimensional quantitative structure-activity relationships.

Fagerberg T, Zoete V, Viatte S, Baumgaertner P, Alves PM, Romero P, Speiser DE, Michielin O.

PLoS One. 2013 Jul 16;8(7):e65590. doi: 10.1371/journal.pone.0065590. Print 2013.

2.

Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.

Maeurer MJ, Chan HW, Karbach J, Salter RD, Knuth A, Lotze MT, Storkus WJ.

Eur J Immunol. 1996 Nov;26(11):2613-23.

PMID:
8921947
3.

HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells.

Chauvin JM, Larrieu P, Sarrabayrouse G, Prévost-Blondel A, Lengagne R, Desfrançois J, Labarrière N, Jotereau F.

J Immunol. 2012 Mar 1;188(5):2102-10. doi: 10.4049/jimmunol.1101807. Epub 2012 Jan 30.

5.

Culture of melanoma cells in 3-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated antigen.

Ghosh S, Rosenthal R, Zajac P, Weber WP, Oertli D, Heberer M, Martin I, Spagnoli GC, Reschner A.

Ann Surg. 2005 Dec;242(6):851-7, discussion 858.

6.

Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity.

Colombetti S, Fagerberg T, Baumgärtner P, Chapatte L, Speiser DE, Rufer N, Michielin O, Lévy F.

J Immunol. 2006 Jun 1;176(11):6560-7.

7.

Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.

Rivoltini L, Loftus DJ, Barracchini K, Arienti F, Mazzocchi A, Biddison WE, Salgaller ML, Appella E, Parmiani G, Marincola FM.

J Immunol. 1996 May 15;156(10):3882-91.

PMID:
8621927
8.

Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL.

Rubio-Godoy V, Dutoit V, Zhao Y, Simon R, Guillaume P, Houghten R, Romero P, Cerottini JC, Pinilla C, Valmori D.

J Immunol. 2002 Nov 15;169(10):5696-707.

9.

Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant.

McArdle SE, Rees RC, Mulcahy KA, Saba J, McIntyre CA, Murray AK.

Cancer Immunol Immunother. 2000 Oct;49(8):417-25.

PMID:
11043848
10.

In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.

Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY.

J Natl Cancer Inst. 1997 Feb 19;89(4):293-300.

11.
12.
13.

T-cell receptors: tugging on the anchor for a tighter hold on the tumor-associated peptide.

Dyson J.

Eur J Immunol. 2015 Feb;45(2):380-2. doi: 10.1002/eji.201445385.

14.

Selection of peptides that bind to the HLA-A2.1 molecule by molecular modelling.

Lim JS, Kim S, Lee HG, Lee KY, Kwon TJ, Kim K.

Mol Immunol. 1996 Feb;33(2):221-30.

PMID:
8649443
15.

Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen.

van Elsas A, van der Burg SH, van der Minne CE, Borghi M, Mourer JS, Melief CJ, Schrier PI.

Eur J Immunol. 1996 Aug;26(8):1683-9.

PMID:
8765006
16.

Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity.

Petersen TR, Buus S, Brunak S, Nissen MH, Sherman LA, Claesson MH.

Scand J Immunol. 2001 Apr;53(4):357-64.

17.

Peptide recognition by two HLA-A2/Tax11-19-specific T cell clones in relationship to their MHC/peptide/TCR crystal structures.

Hausmann S, Biddison WE, Smith KJ, Ding YH, Garboczi DN, Utz U, Wiley DC, Wucherpfennig KW.

J Immunol. 1999 May 1;162(9):5389-97.

19.

Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.

Valmori D, Gervois N, Rimoldi D, Fonteneau JF, Bonelo A, Liénard D, Rivoltini L, Jotereau F, Cerottini JC, Romero P.

J Immunol. 1998 Dec 15;161(12):6956-62. Erratum in: J Immunol 1999 Jul 15;163(2):1093.

20.

Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.

Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J.

Cancer Res. 1997 Oct 15;57(20):4570-7.

Items per page

Supplemental Content

Write to the Help Desk